Trek Therapeutics, PBC
https://www.trektx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Trek Therapeutics, PBC
Tech Transfer Roundup: Vanderbilt Teams With Deerfield; Expands Cancer Pact With Boehringer
Vanderbilt launches new biotech with Deerfield aimed at reworking the drug development paradigm, while also expanding its cancer research work with BI. Grunenthal partners with Katholieke Universiteit Leuven to investigate ion channel modulation approaches in pain.
Deal Watch: CSL Behring's Calimmune Buy Builds On Its Base & Adds Platform Tech
Acquisition of gene therapy company Calimmune expands on CSL Behring's hematology franchise and fits rare disease business model, plus adds platform tech with wide application for CSL's portfolio.
HCV Patient Access: Trek Therapeutics Takes The Road Less Traveled
Trek Therapeutics, a three-year old biotech founded by a group of virology veterans, is testing the conventional wisdom in seeking to carve out a potential $17 billion business in the hotly contested hepatitis C space.
Pipeline Watch: Phase III Read-Outs For Ozanimod, Olaparib And Sapacitabine
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- TREKtx
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice